Crossmark

Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phase

Crossref DOI link: https://doi.org/10.1038/s41375-022-01583-4

Published Online: 2022-05-13

Published Print: 2022-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Sen

Zhang, Xiao-shuai https://orcid.org/0000-0001-5405-0802
Gale, Robert Peter https://orcid.org/0000-0002-9156-1676
Huang, Xiao-jun https://orcid.org/0000-0002-2145-6643
Jiang, Qian https://orcid.org/0000-0001-7131-0522
License Information

Text and Data Mining valid from 2022-05-13

Version of Record valid from 2022-05-13
More Information

Article History

Received: 28 March 2022

Revised: 14 April 2022

Accepted: 20 April 2022

First Online: 13 May 2022

Competing interests

: RPG is a consultant to BeiGene Ltd., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc. and CStone Pharmaceuticals; advisor to Antegene Biotech LLC, Medical Director, FFF Enterprises Inc.; partner, AZAC Inc.; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board: StemRad Ltd.

: Approve by the Ethics Committee of People’s Hospital Beijing compliant with precepts the Helsinki Declaration.

Document is current

Any future updates will be listed below